Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

Hensley ML, Blessing JA, Mannel R, Rose PG.

Gynecol Oncol. 2008 Jun;109(3):329-34. doi: 10.1016/j.ygyno.2008.03.010.

2.

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD.

Gynecol Oncol. 2008 Jun;109(3):323-8. doi: 10.1016/j.ygyno.2008.02.024. Epub 2008 Apr 18.

3.

Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.

Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H.

J Clin Oncol. 2015 Apr 1;33(10):1180-5. doi: 10.1200/JCO.2014.58.3781. Epub 2015 Feb 23.

4.

Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.

Takano T, Niikura H, Ito K, Nagase S, Utsunomiya H, Otsuki T, Toyoshima M, Tokunaga H, Kaiho-Sakuma M, Shiga N, Nagai T, Tanaka S, Otsuki A, Kurosawa H, Shigeta S, Tsuji K, Yamaguchi T, Yaegashi N.

Int J Clin Oncol. 2014 Oct;19(5):897-905. doi: 10.1007/s10147-013-0627-5. Epub 2013 Oct 24.

PMID:
24149774
5.

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR.

J Clin Oncol. 2002 Jun 15;20(12):2824-31.

PMID:
12065559
6.

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.

Hensley ML, Ishill N, Soslow R, Larkin J, Abu-Rustum N, Sabbatini P, Konner J, Tew W, Spriggs D, Aghajanian CA.

Gynecol Oncol. 2009 Mar;112(3):563-7. doi: 10.1016/j.ygyno.2008.11.027. Epub 2009 Jan 9.

PMID:
19135708
7.

Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).

Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, George S, Soslow RA, Baker LH.

Cancer. 2013 Apr 15;119(8):1555-61. doi: 10.1002/cncr.27942. Epub 2013 Jan 18.

8.

Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).

Pautier P, Floquet A, Penel N, Piperno-Neumann S, Isambert N, Rey A, Bompas E, Cioffi A, Delcambre C, Cupissol D, Collin F, Blay JY, Jimenez M, Duffaud F.

Oncologist. 2012;17(9):1213-20. Epub 2012 Aug 20.

9.

A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.

Miller BE, Blessing JA, Stehman FB, Shahin MS, Yamada SD, Secord AA, Warshal DP, Abulafia O, Richards WE, Van Le L.

Gynecol Oncol. 2010 Aug 1;118(2):139-44. doi: 10.1016/j.ygyno.2010.03.024. Epub 2010 May 8.

PMID:
20452658
10.

A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.

Duska LR, Blessing JA, Rotmensch J, Mannel RS, Hanjani P, Rose PG, Dizon DS.

Gynecol Oncol. 2014 Oct;135(1):44-8. doi: 10.1016/j.ygyno.2014.07.101. Epub 2014 Aug 1.

11.

[Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].

Yao Z, Yang S, Zhao Y, Yao S, Guo H, Liu Y.

Zhonghua Zhong Liu Za Zhi. 2014 Jul;36(7):541-5. Chinese.

PMID:
25327662
12.

A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.

Cobo M, Gutiérrez V, Alcaide J, Alés I, Villar E, Gil S, Durán G, Martínez J, Carabantes F, Bretón JJ, Benavides M.

Lung Cancer. 2007 May;56(2):255-62. Epub 2007 Feb 5.

PMID:
17276537
13.

Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Hensley ML, Sill MW, Scribner DR Jr, Brown J, Debernardo RL, Hartenbach EM, McCourt CK, Bosscher JR, Gehrig PA.

Gynecol Oncol. 2009 Dec;115(3):460-5. doi: 10.1016/j.ygyno.2009.09.011. Epub 2009 Oct 6.

14.

Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.

Kornek GV, Haider K, Kwasny W, Raderer M, Schüll B, Payrits T, Depisch D, Kovats E, Lang F, Scheithauer W.

Clin Cancer Res. 2002 May;8(5):1051-6.

15.

Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.

Hensley ML.

Curr Opin Oncol. 2010 Jul;22(4):356-61. doi: 10.1097/CCO.0b013e32833aafef. Review.

PMID:
20520541
16.

Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.

Alexopoulos A, Tryfonopoulos D, Karamouzis MV, Gerasimidis G, Karydas I, Kandilis K, Stavrakakis J, Stavrinides H, Georganta C, Ardavanis A, Rigatos G.

Ann Oncol. 2004 Jan;15(1):95-9.

PMID:
14679126
17.

Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.

Kosmas C, Tsavaris N, Vadiaka M, Stavroyianni N, Koutras A, Malamos N, Onyenadum A, Rokana S, Polyzos A, Kalofonos HP.

Cancer. 2001 Dec 1;92(11):2902-10.

PMID:
11753965
18.

Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.

Cobo Dols M, Villar Chamorro E, Alés Díaz I, Gil Calle S, Alcalde García J, Gutiérrez Calderón V, Carabantes Ocón F, Montesa Pino A, Bretón García JJ, Benavides Orgaz M.

Clin Transl Oncol. 2006 Oct;8(10):742-9.

PMID:
17074673
19.

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.

Look KY, Sandler A, Blessing JA, Lucci JA 3rd, Rose PG; Gynecologic Oncology Group (GOG) Study.

Gynecol Oncol. 2004 Feb;92(2):644-7.

PMID:
14766260
20.

Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.

Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL.

Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. Epub 2007 Feb 2.

PMID:
17273825

Supplemental Content

Support Center